Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib: Case report

American Journal of Transplantation

Volumn 9, Issue 12, 2009, Pages 2851-2854

  Yeganeh, M ^a   Finn, R S ^a   Saab, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; HEPATITIS B ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SORAFENIB; TACROLIMUS; VIRUS DNA;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHEMOEMBOLIZATION; DIARRHEA; DRUG DOSE TITRATION; DRUG MEGADOSE; GRAFT RECIPIENT; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; THORAX SURGERY; TUMOR BIOPSY;

BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES;

EID: 72449198967     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02860.x     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001 94 : 153 156. (Pubitemid 32911406)
2. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with Hepatocellular carcinoma detected during surveillance. Gastroenterology 2004 126 : 1005 1014.
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small Hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
4. Bismuth H, Majno PE, Adam R. Liver transplantation for Hepatocellular carcinoma. Semin Liver Dis 1999 19 : 311 322.
5. Jonas S, Bechstein WO, Steinmuller T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for Hepatocellular carcinoma in cirrhosis. Hepatology 2001 33 : 1080 1086.
6. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with Hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003 21 : 4329 4335.
7. Marsh JW, Dvorchik I, Subotin M et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot study. Hepatology 1997 26 : 444 450.
8. Iwatsuki S, Starzl TE, Sheahan DG et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991 214 : 221 228.
9. Löhe F, Angele MK, Gerbes AL, Lohrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005 31 : 994 999.
10. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004 40 : 1474 1484.
11. Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: Is immunosuppression a factor? Liver Transpl 2005 11 : 494 496. (Pubitemid 40704059)
12. Regalia E, Fassati LR, Valente U et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998 5 : 29 34.
13. Schlitt HJ, Neipp M, Weimann A et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999 17 : 324 331. (Pubitemid 29022410)
14. Roayaie S, Schwartz JD, Sung MW et al. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 2004 10 : 534 540.
15. Liu L, Cao Y, Chen C, Zhang X et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006 66 : 11851 11858.
16. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 : 378 390.
17. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009 44 (Suppl 19 136 141.
18. Ng IO, Liu CL, Fan ST et al. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000 113 : 355 363.
19. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989 58 : 137 171. (Pubitemid 19172967)
20. Park JG, Lee SK, Hong IG et al. MDR1 gene expression: Its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994 86 : 700 705.
21. Cheng A, Kang Y, Chen C et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008 26 : 215.
22. So BJ, Bekaii-Saab T, Bloomston MA et al. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 2008 1 : 18.
23. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004 10 : 1301 1311.
24. Del Poggio P, Mattiello M, Gilardoni L et al. The mysterious case of spontaneous disappearance of hepatocellular carcinoma. Dig Liver Dis 2009 41 : 21 25.
25. Kojima H, Tanigawa N, Kariya S et al. A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. Radiat Med 2006 24 : 139 142.